康莱特辅助化疗对晚期非小细胞肺癌患者生存期的影响  

Survival impact of Kanglaite adjuvant chemotherapy in advanced non-small cell lung cancer

作　　者：毛良平[1] 孙锎[1] 张萍[1] 

机构地区：[1]重庆三峡中心医院呼吸内科,重庆404000

出　　处：《中国医学前沿杂志（电子版）》2014年第7期51-54,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的探讨康莱特辅助化疗对晚期非小细胞肺癌(NSCLC)患者生存期的影响。方法将126例确诊为晚期NSCLC患者随机分为观察组与对照组,每组各63例,对照组患者仅行化疗,观察组患者采用化疗联合康莱特治疗,比较两组患者的近期疗效并随访生存期情况。结果观察组治疗有效率为47.6%,对照组为20.6%,观察组患者1年生存率为68.3%,对照组为49.2%,观察组患者2年生存率为36.5%,对照组为14.3%,两组比较差异显著(P<0.05),两组患者进行至少24个月的随访后,平均生存期分别为(689.4±164.1)天和(427.8±148.3)天(P<0.05),观察组患者中位生存时间为568天,对照组为379天。结论康莱特联合辅助化疗可有效提升晚期NSCLC患者的近期疗效及2年生存率。Objective To explore survival impact of Kanglaite adjuvant chemotherapy in advanced nonsmall cell lung cancer. Method 126 patients with advanced non-small cell cancer patients were randomly divided into observation group and control group, each group contained 63 cases, the control group treated with chemotherapy, and the observation group were treated with chemotherapy combined Kanglaite, recently efficacy were observed and survival were followed-up. Result The effective rate was 47.6% in the observation group, and that was 20.6% in the control group, the 1-year survival rate was 68.3% and 49.2% in the observation group and the control group, the 2-year survival rate was 36.5 % and 14.3 % in the observation group and the control group,（P〈0.05）, the average survival period of observation group and control group was（689.4±164.1） daysand（427.8±148.3） days with least 24 months followed-up, the median survival time was 568 days and 379 days in the observation group and the control group. Conclusion Kanglaite adjuvant chemotherapy can enhance the short-term efficacy of non-small cell lung cance and two years survival rate.

关 键 词：康莱特 化疗 晚期非小细胞肺癌 生存期 

分 类 号：R734.2[医药卫生—肿瘤]